Amigo and Eucalyptus Partner to Deploy AI Health Agents in Virtual Clinics

AI health platform Amigo has announced a strategic partnership with Australian telehealth company Eucalyptus to integrate artificial intelligence agents into Eucalyptus' portfolio of specialized virtual clinics. The collaboration will initially focus on deploying an AI health assistant for Juniper, Eucalyptus' women's weight management clinic, before expanding to other brands in the company's healthcare ecosystem.

Amigo specializes in developing customized AI agents tailored to specific patient care requirements. The platform's capabilities span clinical triage and routing, pre- and post-appointment coordination, virtual nursing support, nutrition and weight loss guidance, primary care decision support, biomarker assessment, personalized health coaching, and chronic care management. This comprehensive suite of AI-powered tools will be integrated into Eucalyptus' existing infrastructure to enhance patient care delivery.

Eucalyptus operates five distinct telehealth clinics targeting specific health concerns: Kin for reproductive care, Pilot for men's hair loss and sexual health, Juniper for women's weight management, Software for skincare, and Compound for men's preventive health and performance. Each clinic connects patients with certified practitioners, delivers treatments, and provides continuous care management through digital channels.

"We are committed to pioneering the future of digital healthcare," stated Benny Kleist, cofounder and chief strategy officer of Eucalyptus. "Working with Amigo represents a significant step forward in our mission to make quality healthcare more accessible, allowing our clinical teams to ensure every patient receives the always-on, personalized support they need to achieve their health goals."

The partnership comes as Eucalyptus continues its growth trajectory following significant funding rounds. In 2022, the Sydney-based company raised A$60 million ($42 million) in a Series C round led by BOND, an early investor in companies like Airbnb and Canva. The round included participation from existing investors Blackbird, NewView, W23, Airtree, OneVentures, and Athletic Ventures. The company allocated these funds toward software development and expanding into the United Kingdom market.

Prior to the Series C, Eucalyptus secured A$30 million ($22.4 million) in 2021 through a Series B funding round led by NewView Capital, the Silicon Valley-based firm that has backed other digital health companies including 23andMe and Hims & Hers. That round saw participation from previous investors Blackbird Ventures and W23, along with new investor AirTree Ventures.

The integration of Amigo's AI health agents represents a strategic move to scale personalized care delivery across Eucalyptus' growing patient base. By automating routine clinical tasks and providing round-the-clock support, the AI agents will enable Eucalyptus' clinical teams to focus on complex patient needs while maintaining high-quality care standards. The initial deployment at Juniper will serve as a proof of concept before the technology rolls out to Eucalyptus' other specialty clinics, potentially transforming how virtual healthcare services are delivered across multiple therapeutic areas.